Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab for Coronary Atherosclerosis in AMI (ZEPHYR)
NCT07301034Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Countries
- 6
01
Overview
A Phase 3 trial of ziltivekimab in myocardial infarction (MI), sponsored by Novo Nordisk. Started Dec 2025; status: recruiting.
02
Drugs
ziltivekimab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT07301034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301034.